AU2008347400B2 - Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives - Google Patents

Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives Download PDF

Info

Publication number
AU2008347400B2
AU2008347400B2 AU2008347400A AU2008347400A AU2008347400B2 AU 2008347400 B2 AU2008347400 B2 AU 2008347400B2 AU 2008347400 A AU2008347400 A AU 2008347400A AU 2008347400 A AU2008347400 A AU 2008347400A AU 2008347400 B2 AU2008347400 B2 AU 2008347400B2
Authority
AU
Australia
Prior art keywords
imiquimod
treatment
cells
colorectal
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008347400A
Other languages
English (en)
Other versions
AU2008347400A1 (en
Inventor
Joachim Maus
Ursula Petzold
Istvan Szelenyi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meda AB
Original Assignee
Meda AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40419193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2008347400(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Meda AB filed Critical Meda AB
Publication of AU2008347400A1 publication Critical patent/AU2008347400A1/en
Application granted granted Critical
Publication of AU2008347400B2 publication Critical patent/AU2008347400B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AU2008347400A 2008-01-15 2008-12-23 Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives Ceased AU2008347400B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US645908P 2008-01-15 2008-01-15
US61/006,459 2008-01-15
PCT/EP2008/011088 WO2009089900A1 (en) 2008-01-15 2008-12-23 Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives

Publications (2)

Publication Number Publication Date
AU2008347400A1 AU2008347400A1 (en) 2009-07-23
AU2008347400B2 true AU2008347400B2 (en) 2014-12-11

Family

ID=40419193

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008347400A Ceased AU2008347400B2 (en) 2008-01-15 2008-12-23 Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives

Country Status (15)

Country Link
US (1) US8008319B2 (enExample)
EP (1) EP2237780A1 (enExample)
JP (1) JP2011509956A (enExample)
CN (1) CN101909624A (enExample)
AU (1) AU2008347400B2 (enExample)
BR (1) BRPI0822002A2 (enExample)
CA (1) CA2708559C (enExample)
EA (1) EA018579B1 (enExample)
GE (1) GEP20125605B (enExample)
IL (1) IL205819A (enExample)
MX (1) MX2010007699A (enExample)
NZ (1) NZ586161A (enExample)
UA (1) UA101339C2 (enExample)
WO (1) WO2009089900A1 (enExample)
ZA (1) ZA201003906B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012004706A (es) 2009-10-22 2012-06-08 Gilead Sciences Inc Derivados de purina o deazapurina utiles para el tratamiento de (inter alia) infecciones virales.
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
EP3092255A4 (en) 2014-01-10 2017-09-20 Birdie Biopharmaceuticals Inc. Compounds and compositions for treating egfr expressing tumors
CA2954446A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-her2组合
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于治疗肿瘤的抗-cd20组合
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
KR20200019226A (ko) 2017-06-23 2020-02-21 버디 바이오파마슈티칼즈, 인크. 약학 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2078547C1 (ru) * 1995-11-28 1997-05-10 Центральный научно-исследовательский рентгено-радиологический институт МЗМП РФ Способ лечения полипоза желудка и двенадцатиперстной кишки
UA74852C2 (en) * 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
WO2002053138A2 (en) * 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
US20060193789A1 (en) * 2002-10-25 2006-08-31 Foamix Ltd. Film forming foamable composition
JP2007511575A (ja) * 2003-11-21 2007-05-10 ノバルティス アクチエンゲゼルシャフト タンパク質キナーゼ阻害剤としての１ｈ−イミダゾキノリン誘導体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DIAKOMANOLIS, E., ET AL, "Treatment of High-Grade Vaginal Intraepithelial Neoplasia with Imiquimod Cream". The New England Journal of Medicine, 2002, vol. 347, no. 5, page 374 *
FLESHNER, P.R., ET AL, "Practice Parameters for Anal Squamous Neoplasms". Diseases of the Colon & Rectum, 2008, vol. 51, no. 1, pages 2-9 *
LIPKA, E., ET AL, "Evaluation of Imiquimod and Analogues with Respect to their Oral Delivery Potential". Proceedings of the Controlled Release Society, 1997, no. 24, pages 337-338 *
SIDKY, Y.A., ET AL, "Inhibition of Murine Tumor Growth by an Interferon-inducing Imidazoquinolinamine". Cancer Research, 1992, vol. 52, pages 3528-3533 *

Also Published As

Publication number Publication date
EA201001164A1 (ru) 2010-12-30
EA018579B1 (ru) 2013-09-30
NZ586161A (en) 2012-05-25
EP2237780A1 (en) 2010-10-13
ZA201003906B (en) 2011-03-30
CA2708559C (en) 2015-10-06
IL205819A0 (en) 2010-11-30
BRPI0822002A2 (pt) 2015-10-13
WO2009089900A1 (en) 2009-07-23
UA101339C2 (ru) 2013-03-25
US20090182005A1 (en) 2009-07-16
CA2708559A1 (en) 2009-07-23
CN101909624A (zh) 2010-12-08
MX2010007699A (es) 2010-08-04
US8008319B2 (en) 2011-08-30
JP2011509956A (ja) 2011-03-31
IL205819A (en) 2013-02-28
AU2008347400A1 (en) 2009-07-23
GEP20125605B (en) 2012-08-10

Similar Documents

Publication Publication Date Title
CA2708559C (en) Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives
Du et al. cGAS-STING signaling in cancer immunity and immunotherapy
Carvalho et al. Radiotherapy and immune response: the systemic effects of a local treatment
Zheng et al. Luteolin exhibits synergistic therapeutic efficacy with erastin to induce ferroptosis in colon cancer cells through the HIC1-mediated inhibition of GPX4 expression
Xia et al. Vorinostat upregulates MICA via the PI3K/Akt pathway to enhance the ability of natural killer cells to kill tumor cells
Spitler A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma.
Feng et al. Effect of grape procyanidins on tumor angiogenesis in liver cancer xenograft models
EP2512469B1 (en) 3-(indolyl)-or 3-(azaindolyl)- 4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarzinoma
JP2021169474A (ja) がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法
Hodges et al. CoQ10: could it have a role in cancer management?
Korets et al. Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer
Xu et al. Inhibition of NLRP3 inflammasome activation in myeloid-derived suppressor cells by andrographolide sulfonate contributes to 5-FU sensitization in mice
Garcia-Martinez et al. Are antiangiogenics a good ‘partner’for immunotherapy in ovarian cancer?
Wang et al. Thalidomide suppresses breast cancer tumor growth by inhibiting tumor-associated macrophage accumulation in breast tumor-bearing mice
Sun et al. Dehydrocostus lactone alleviates irinotecan-induced intestinal mucositis by blocking TLR4/MD2 complex formation
CN117919234A (zh) 一种萘酰胺化合物治疗耐药性肿瘤的用途
JP2018517759A (ja) カルボプラチンを含む組成物及び用途
Yu et al. Combination of apatinib with apo-IDO1 inhibitor for the treatment of colorectal cancer
Zadeh et al. Autophagy-related chemoradiotherapy sensitivity in non-small cell lung cancer (NSCLC)
Xu et al. Radiation-based immunogenic vaccine combined with a macrophage “checkpoint inhibitor” for boosting innate and adaptive immunity against metastatic colon cancers
Torki et al. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells
JP7285001B2 (ja) サフラナール製剤による肝臓癌治療の方法
Guo et al. Remodeling the immune microenvironment for gastric cancer therapy through antagonism of prostaglandin E2 receptor 4
CN115501231A (zh) 预防和/或治疗肝癌的联用药物组合物及其应用
Feng et al. Liriope muscari baily saponin C induces apoptosis and autophagy in HCT116 cells via ROS generation

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 23 DEC 2012 TO 23 JUL 2013 IN WHICH TO PAY A CONTINUATION FEE HAS BEEN FILED .

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A CONTINUATION FEE HAS BEEN EXTENDED TO 23 JUL 2013 .

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired